Real-time Estimate
Cboe BZX
12:26:28 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
10.08
USD
|
-0.40%
|
|
+2.58%
|
+24.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,165
|
2,818
|
952.1
|
728.5
|
485.3
|
597.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,165
|
2,818
|
722.6
|
301.3
|
147.6
|
429.5
|
427.4
|
394.6
|
P/E ratio
|
-7.95
x
|
-33.3
x
|
-5.95
x
|
-3.2
x
|
-1.76
x
|
-3.24
x
|
-3.49
x
|
-4.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
681
x
|
228
x
|
199
x
|
43.3
x
|
9.27
x
|
EV / Revenue
|
-
|
-
|
-
|
282
x
|
69.3
x
|
143
x
|
31
x
|
6.13
x
|
EV / EBITDA
|
-
|
-
|
-4.49
x
|
-1.36
x
|
-0.58
x
|
-2.04
x
|
-1.89
x
|
-2.01
x
|
EV / FCF
|
-24.6
x
|
-33.2
x
|
-5.25
x
|
-18.8
x
|
-0.72
x
|
-2.5
x
|
-2.14
x
|
-1.91
x
|
FCF Yield
|
-4.07%
|
-3.01%
|
-19%
|
-5.33%
|
-139%
|
-39.9%
|
-46.8%
|
-52.4%
|
Price to Book
|
-
|
-
|
4.04
x
|
2.46
x
|
-
|
2.34
x
|
3.16
x
|
3.29
x
|
Nbr of stocks (in thousands)
|
30,536
|
31,922
|
32,462
|
42,827
|
58,394
|
59,024
|
-
|
-
|
Reference price
2 |
38.16
|
88.29
|
29.33
|
17.01
|
8.310
|
10.12
|
10.12
|
10.12
|
Announcement Date
|
20-03-26
|
21-03-30
|
22-03-29
|
23-03-30
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1.069
|
2.13
|
3.009
|
13.78
|
64.41
|
EBITDA
1 |
-
|
-
|
-160.8
|
-221.9
|
-255.2
|
-210.9
|
-226.7
|
-196.3
|
EBIT
1 |
-44.5
|
-83.28
|
-165.3
|
-228
|
-263.5
|
-205.1
|
-230.7
|
-217.3
|
Operating Margin
|
-
|
-
|
-
|
-21,324.23%
|
-12,369.06%
|
-6,816.11%
|
-1,673.96%
|
-337.38%
|
Earnings before Tax (EBT)
1 |
-43.13
|
-81.36
|
-165.2
|
-221.1
|
-245.7
|
-200.4
|
-226.9
|
-213.2
|
Net income
1 |
-43.13
|
-81.36
|
-165.2
|
-221.1
|
-246.4
|
-192.3
|
-223
|
-212.6
|
Net margin
|
-
|
-
|
-
|
-20,683.07%
|
-11,568.83%
|
-6,389.23%
|
-1,618.06%
|
-330.01%
|
EPS
2 |
-4.800
|
-2.650
|
-4.930
|
-5.320
|
-4.710
|
-3.119
|
-2.900
|
-2.311
|
Free Cash Flow
1 |
-47.45
|
-84.8
|
-137.6
|
-16.06
|
-204.6
|
-171.5
|
-200
|
-206.9
|
FCF margin
|
-
|
-
|
-
|
-1,502.25%
|
-9,606.2%
|
-5,699.57%
|
-1,450.93%
|
-321.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-26
|
21-03-30
|
22-03-29
|
23-03-30
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
0.366
|
0.331
|
0.372
|
0.522
|
0.448
|
0.509
|
0.651
|
0.497
|
0.7464
|
0.8188
|
0.8469
|
EBITDA
|
-
|
-
|
-
|
-
|
-54.37
|
-
|
-66.04
|
-64.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-50.68
|
-51.96
|
-59.22
|
-60.51
|
-56.26
|
-63.9
|
-68.21
|
-66.76
|
-65.12
|
-53.86
|
-52.35
|
-52.55
|
-53.25
|
Operating Margin
|
-
|
-
|
-16,181.42%
|
-18,281.57%
|
-15,124.73%
|
-12,240.61%
|
-15,225%
|
-13,115.91%
|
-10,002.92%
|
-10,836.22%
|
-7,013.08%
|
-6,418.79%
|
-6,287.93%
|
Earnings before Tax (EBT)
1 |
-50.64
|
-51.89
|
-58.6
|
-58.04
|
-52.58
|
-59.22
|
-64.31
|
-61.75
|
-60.45
|
-49.82
|
-49.25
|
-49.5
|
-50.28
|
Net income
1 |
-50.64
|
-51.89
|
-58.6
|
-58.04
|
-52.58
|
-59.31
|
-64.42
|
-61.99
|
-60.7
|
-49.82
|
-49.57
|
-49.69
|
-50.37
|
Net margin
|
-
|
-
|
-16,009.56%
|
-17,533.84%
|
-14,133.33%
|
-11,361.88%
|
-14,380.13%
|
-12,178.59%
|
-9,323.35%
|
-10,023.34%
|
-6,640.58%
|
-6,069.49%
|
-5,948.28%
|
EPS
2 |
-1.500
|
-1.530
|
-1.330
|
-1.320
|
-1.190
|
-1.330
|
-1.430
|
-1.040
|
-1.010
|
-0.8300
|
-0.8217
|
-0.8218
|
-0.7759
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-29
|
22-05-09
|
22-08-08
|
22-11-03
|
23-03-30
|
23-05-12
|
23-08-03
|
23-11-13
|
24-03-07
|
24-05-08
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
230
|
427
|
338
|
168
|
170
|
203
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-47.5
|
-84.8
|
-138
|
-16.1
|
-205
|
-172
|
-200
|
-207
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-52.7%
|
-83.1%
|
-100%
|
-126%
|
-672%
|
-369%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-54.5%
|
-52.6%
|
-27.4%
|
-32.5%
|
-29.4%
|
Assets
1 |
-
|
-
|
-
|
405.8
|
468.5
|
701.9
|
687
|
723.1
|
Book Value Per Share
2 |
-
|
-
|
7.250
|
6.910
|
-
|
4.330
|
3.200
|
3.080
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-0.1400
|
-3.670
|
-2.420
|
-2.510
|
-
|
Capex
1 |
2.34
|
17.5
|
13.2
|
10.2
|
12.4
|
13
|
13.5
|
13.7
|
Capex / Sales
|
-
|
-
|
-
|
954.72%
|
581.27%
|
432.04%
|
97.92%
|
21.25%
|
Announcement Date
|
20-03-26
|
21-03-30
|
22-03-29
|
23-03-30
|
24-03-07
|
-
|
-
|
-
|
Last Close Price
10.12
USD Average target price
21.4
USD Spread / Average Target +111.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.31% | 597M | | +3.26% | 108B | | +11.08% | 104B | | +1.28% | 22.33B | | -11.89% | 22.19B | | -7.05% | 18.69B | | -38.36% | 17.74B | | -9.90% | 17.64B | | +4.34% | 14.05B | | +34.95% | 12.51B |
Bio Therapeutic Drugs
|